Table 4. Correlations between CSF GABA, clinical symptoms and cognitive performance in FEP patients.
| r | P-valuea | |
|---|---|---|
| PANSS | ||
| Positive | −0.26 | 0.05 |
| Negative | −0.19 | 0.12 |
| General | −0.31 | 0.02b |
| Total | −0.30 | 0.03b |
| Severity of illness | ||
| GAF symptom dimension | 0.31 | 0.02 |
| GAF functioning dimension | 0.24 | 0.06 |
| CGI score | −0.38 | 0.007 |
| Cognitive tests | ||
| CPT-IP | 0.37 | 0.01c |
| TMT | −0.038 | 0.41 |
| BACS-SC | −0.028 | 0.43 |
| WMS-III | 0.016 | 0.46 |
| BVMT-R | −0.095 | 0.28 |
| HVLT-R | −0.12 | 0.24 |
Abbreviations: BACS-SC, Brief Assessment of Cognition in Schizophrenia Symbol Coding; BVMT-R, Brief Visuospatial Memory Test-Revised; CGI, Clinical Global Impression; CPT-IP, Continuous Performance Test-Identical Pairs; CSF, cerebrospinal fluid; FEP, first-episode psychosis; GABA, γ-aminobutyric acid; GAF, Global Assessment of Functioning; HVLT-R, Hopkins Verbal Learning Test-Revised; PANSS, Positive and Negative Syndrome Scale; TMT, Trail Making Test; WMS-III, Wechsler Memory Scale-3rd Edition.
a
Pearson’s correlation.
b
Significant also after principal component analysis.
c
Bonferroni-corrrected, α-value=0.0083.